simvastatin has been researched along with Granulocytic Leukemia, Chronic in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, D; Chen, K; Chen, Q; Deng, M; Ding, L; Gao, D; Jiang, Y; Li, G; Xu, B; Zhang, H | 1 |
| Asari, K; Chuah, C; Kok, ZH; Lam, YH; Ng, BL; Saunders, V; Sun, WT; White, DL; Xiang, W | 1 |
| Adriano, E; Balestrino, M | 1 |
| Ahn, KS; Kim, SM; Lee, EJ; Lee, JH; Lee, SG; Nam, D; Shim, BS; Um, JY; Yang, WM | 1 |
| Chuan, LM; Hu, Q; Huang, B; Huang, WF; Liu, W; Xiao, DW; Xu, GQ; Yang, YC; Zeng, YL; Zhou, DA | 1 |
| Chen, R; Li, D; Mu, S; Xiao, W | 1 |
| Huh, JY; Kang, MS; Kim, M; Kim, TY; Kim, Y; Lee, DS; Min, HJ; Oh, B | 1 |
| Beck, J; Bond, E; Capdeville, R; Dutreix, C; Fischer, T; Huber, C; Mehring, G; Meinhardt, P; Milosavljev, S; O'Brien, SG; Peng, B | 1 |
1 trial(s) available for simvastatin and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.
Topics: Administration, Oral; Adult; Area Under Curve; Benzamides; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Simvastatin | 2003 |
7 other study(ies) available for simvastatin and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Simvastatin; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2021 |
Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Protein-Tyrosine Kinases; Pyrimidines; Simvastatin | 2021 |
Statin-induced myopathy prevented by creatine administration.
Topics: Aged; Amaurosis Fugax; Anticholesteremic Agents; Carotid Stenosis; Cholesterol, LDL; Creatine; Drug Therapy, Combination; Ezetimibe; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myalgia; Pyrimidines; Simvastatin; Treatment Outcome | 2018 |
Simvastatin in combination with bergamottin potentiates TNF-induced apoptosis through modulation of NF-κB signalling pathway in human chronic myelogenous leukaemia.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Furocoumarins; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Matrix Metalloproteinase 9; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Proteolysis; S Phase Cell Cycle Checkpoints; Signal Transduction; Simvastatin; Time Factors; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2016 |
In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Nuclear Proteins; Simvastatin; Xenograft Model Antitumor Assays | 2008 |
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Death; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Reactive Oxygen Species; Simvastatin | 2011 |
Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Pyrimidines; Simvastatin; Xenograft Model Antitumor Assays | 2013 |